Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients

In this study, the effect-implementation mixed research design was adopted. The patients were assigned to the intervention group and the control group at a ratio of 2 : 1 by the central stratified randomization method. The stratification factors were four phenotypes of psychosomatic symptoms ( anxiety and depression, sleep disorders, fatigue and mixed symptoms ). The intervention group was determined by the three-stage conversation model of doctor-patient joint decision-making, and the personalized acupuncture intervention program was determined. Combined with the patient 's own needs and service accessibility, the hospital intervention subgroup or the medical-social-home intervention subgroup scenario was determined. The control group was given routine nursing. Because the intervention requires informed interaction between doctors and patients, only outcome evaluators and data analysts are blinded. The intervention period was 8 weeks of treatment and 4 weeks of follow-up, a total of 12 weeks. Based on the evaluation of the effect of acupuncture intervention on the improvement of psychosomatic symptoms, the study was guided by the CFIR framework to evaluate the implementation of the hospital intervention subgroup and the medical-social-family intervention subgroup formed after the joint decision-making of doctors and patients, identify the implementation obstacles and promotion factors, and evaluate the implementation outcomes such as acceptability, feasibility, implementation loyalty and coverage.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

216

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Tianjin, Kina
        • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  1. Female, aged 18-70 years

  2. Histologically or cytologically confirmed breast cancer (AJCC 8th Edition Stage 0-IV)

  3. At least one psychosomatic symptom meeting the following criteria:

    • Anxiety or depression: Hospital Anxiety and Depression Scale (HADS) anxiety or depression subscale ≥ 8
    • Sleep disorder: Pittsburgh Sleep Quality Index (PSQI) total score ≥ 8
    • Cancer-related fatigue: Brief Fatigue Inventory (BFI) total score ≥ 4
  4. Expected survival ≥ 1 year

  5. Alert, conscious, with basic communication ability, able to complete questionnaire assessments

  6. Signed informed consent by patient or legal guardian

Exclusion Criteria:

  1. Severe mental disorders (e.g., schizophrenia, bipolar disorder) or lack of civil capacity
  2. Unsuitable for auricular acupressure: local auricular skin damage/infection/allergy to Vaccaria seeds or tape
  3. Currently receiving other acupuncture/acupressure interventions, or unable to discontinue during the study period
  4. Unsuitable for acupuncture: bleeding tendency (e.g., coagulopathy, purpura), or local acupoint damage
  5. Severe cardiac, hepatic, or renal failure, or cachexia
  6. Pregnant or breastfeeding women

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Eksperimentell: Intervention Group

Participants receive personalized acupuncture intervention (acupuncture and/or auricular acupressure) determined through the Shared Decision Making three-stage conversation model, on top of standard care. Patients choose either hospital-based or hospital-community-family intervention sub-group based on personal needs and service accessibility. Treatment duration: 8 weeks intervention + 4 weeks follow-up.

Ingen inngripen: Control Group

Participants receive standard care only, including diet, exercise, emotional regulation guidance, and health education based on the Breast Cancer Psychosomatic Health Education Manual. No active acupuncture intervention for psychosomatic symptoms during the study period.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Functional Assessment of Cancer Therapy-Breast, FACT-B
Tidsramme: 8 weeks

Instruments for assessing Quality of Life (QoL) among breast cancer patients;Functional Assessment of Cancer Therapy-Breast (FACT-B Version 4.0) Uniform response options: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much Unified scoring rule for all subscales and total scores: Higher scores indicate better quality of life among breast cancer patients; lower scores reflect more severe physical, emotional, social and breast-specific distress.

8 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hospital anxiety and depression scale,HADS
Tidsramme: 8 weeks

Hospital Anxiety and Depression Scale (HADS) Full Scoring Standard Specifications Subscale 1: Anxiety subscale (HADS-A) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe anxiety symptoms. Subscale 2: Depression subscale (HADS-D) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe depressive symptoms. HADS total score Composition: HADS-A score + HADS-D score Minimum score: 0 Maximum score: 42 Interpretation: Higher total scores indicate more severe combined anxiety and depression symptoms.

Supplementary Response Option Rule (Standard HADS 4-point Likert) All items adopt 4-point scoring from 0 to 3; higher single item scores stand for worse emotional conditions.

8 weeks
Pittsburgh sleep quality index,PSQI
Tidsramme: 8 weeks

Pittsburgh Sleep Quality Index (PSQI) Full Scoring Standard Description PSQI component subscores (7 sleep dimensions) Each component score range: 0-3 PSQI global total score Full name: Pittsburgh Sleep Quality Index Global Score Minimum score: 0 Maximum score: 21 Interpretation: Higher global scores represent worse overall sleep quality; lower scores indicate better sleep quality.

8 weeks
Brief Fatigue Inventory,BFI
Tidsramme: 8 weeks

Brief Fatigue Inventory (BFI) Full Scoring Standard Description Single item scoring range for each fatigue item: 0-10 BFI Global Fatigue Severity Score Full name: Brief Fatigue Inventory Global Fatigue Severity Score Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe fatigue; lower scores represent milder fatigue status.

Supplement The total global score is the average of all 9 items of the BFI. Each item uses a 0-10 numerical rating scale, where 0 = no fatigue at all and 10 = worst fatigue imaginable.

8 weeks
Brief Pain Inventory,BPI
Tidsramme: 8 weeks

Brief Pain Inventory (BPI) Full Scoring Standard Description Single item scoring range: Each pain-related item is scored on a 0-10 numeric rating scale (0 = no pain, 10 = worst pain imaginable) BPI Pain Severity Score Full name: Brief Pain Inventory Pain Severity Score Composition: Average score of 4 pain severity items (worst pain, least pain, average pain, pain right now) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores mean greater pain severity BPI Pain Interference Score Full name: Brief Pain Inventory Pain Interference Score Composition: Average score of 7 pain interference items (interference with general activity, mood, walking ability, normal work, relations with others, sleep, enjoyment of life) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe interference of pain on daily life

8 weeks

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Acceptability of the intervention
Tidsramme: 8 weeks

Acceptability of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater acceptability. A total score of ≥16 indicates good acceptability.

8 weeks
Feasibility of the intervention
Tidsramme: 8 weeks

Feasibility of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater feasibility. A total score of ≥16 indicates good feasibility.

8 weeks
Implementation Fidelity: Auricular Acupressure Treatment Adherence Rate
Tidsramme: 8 weeks

Auricular acupressure treatment adherence rate = (Number of auricular acupressure sessions actually completed / Number of required sessions) × 100%. An adherence rate of ≥80% indicates good adherence.

8 weeks
Implementation Fidelity: Self-Pressing Adherence Rate
Tidsramme: 8 weeks

Self-pressing adherence was assessed by recording the daily frequency of self-pressing in patient logs and verifying the records by asking participants during follow-up visits. An adherence rate of ≥90% indicates good adherence.

8 weeks
Coverage of the intervention
Tidsramme: 8 weeks

Coverage was defined as the proportion of eligible breast cancer patients with psychosomatic symptoms who participated in the study.

8 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. oktober 2026

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

18. oktober 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere